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Background: Ovarian carcinoma is the leading cause of cancer death worldwide among gynecological
malignancies, and the majority of cases are related with recurrence and chemoresistance. Cancer stem cells (CSCs)
are believed to be one of the causes of recurrent or chemoresistant ovarian cancer, and microRNAs are regulatory
molecules newly implicated to control a variety of cellular processes, including CSCs. Therefore, we identified
ovarian CSC-specific microRNAs and investigated their clinicopathological implication in ovarian carcinomas.
Methods: We isolated ALDH1 (+) cell population using the Aldefluor assay, and examined the differential
expression pattern of miRNAs between ALDH1 (+) and ALDH1 (−) cells using a high-throughput microRNA
microarray. We further investigated the expression patterns of differentially expressed miRNAs in human ovarian
cancer samples using the real-time reverse transcription-polymerase chain reaction and analyzed their clinical
impact in patients with ovarian cancer.
Results: We found that high ALDH1 expression was associated with chemoresistance in in vitro and ex vivo samples
(p = 0.024). We identified six miRNAs, including miR-23b, miR-27a, miR-27b, miR-346, miR-424, and miR-503,
overexpressed in ALDH1 (+) cells, and they were significantly upregulated in chemoresistant ovarian cancer cells
(1.4 ~ 3.5-fold) and tumor samples (2.8 ~ 5.5-fold) compared with chemosensitive group. Upregulation of ALDH1
(p = 0.019) and miR-503 (p = 0.033) correlated with high clinical stage, and upregulation of miR-27a was related with
distant metastasis (p = 0.046) in patients with ovarian cancer.
Conclusion: Our findings indicate that ALDH1 is a useful marker for enriching ovarian CSCs, and high expression of
ALDH1 and its related miRNAs, particularly miR-23b, miR-27b, miR-424, and miR-503, are significantly implicated in
chemoresistance and tumor progression in ovarian cancer.
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Ovarian carcinoma is the leading cause of gynecologic
cancer deaths [1], and > 70% of patients with advanced
stage develop a recurrence within 5 years [2]. Despite
multimodality treatment, many patients with advanced
disease become refractory to conventional chemothera-
peutic agents [3], resulting in recurrence and death.
Emerging evidence suggests that cancer stem cells (CSCs)
represent the most tumorigenic and chemotherapy-
resistant cells within a heterogeneous tumor mass [4,5].* Correspondence: ercir@cha.ac.kr; hjahn@cha.ac.kr
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reproduction in any medium, provided the orCSCs are characterized by their ability to self-renew, modu-
late, and balance differentiation according to the genetic
background and environmental stimuli [6]. CSCs can sur-
vive conventional treatments and become recurrent tumors
that are more chemoresistant and more aggressive [7].
However, the CSC regulatory mechanisms at the molecular
level are poorly understood. The recent discovery of
microRNAs (miRNA) have opened a field of gene regula-
tion implicated in tumorigenesis and CSC modulation [8].
MiRNAs, noncoding regulatory RNAs of 21–25 nucle-
otides [9], are critical regulators of post-transcriptional
gene expression. MiRNAs are transcribed as long RNA
precursors (primary miRNAs) that are processed to yield
mature miRNAs of approximately 25 nucleotides in. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinicopathological characteristics of patients
with ovarian serous carcinoma (n = 34)
Chemosensitive Chemoresistant
Age (yrs) 51.5 ± 18.5 64.5 ± 18.5
Stage I/II 4(11.76%) 0(0.00%)
III/IV 15(44.12%) 15(44.12%)
LN Negative 9(26.47%) 5(14.71%)
Positive 10(29.41%) 10(29.41%)
Metastasis Negative 14(41.17%) 10(29.41%)
Positive 5(14.71%) 5(14.71%)
Total 19(55.88%) 15(44.12%)
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miRNAs are incorporated into the RNA-induced silen-
cing complex and then target the 3′ untranslated region
(3′-UTR) of a specific mRNA by base pairing, leading to
translational repression or mRNA degradation [10].
MiRNAs have been predicted to regulate the expression of
up to 70% of human genes, implying a potential role for
miRNAs in the regulation of nearly every genetic pathway
[11,12]. Taken together, understanding the regulatory role
of miRNAs in CSCs may lead to a better understanding of
the molecular events involved in chemoresistance and
could lead to the development of a new therapeutic target.
In this study, we isolated the ALDH1 (+) cell popula-
tion enriched CSCs using the Aldefluor assay, and exam-
ined the differential expression pattern of miRNAs
between ALDH1 (+) and ALDH1 (−) cells using a high-
throughput microRNA microarray to identify miRNAs
regulating ovarian CSCs. We further investigated the ex-
pression patterns and their clinical impact of differen-
tially expressed miRNAs in human ovarian cancer
samples using the real-time reverse transcription poly-
merase chain reaction (qRT-PCR).
Methods
Cell lines and tumor samples
The human ovarian carcinoma cell line SKOV3 was
obtained from the American Type Culture Collection
(Manassas, VA, USA). Paclitaxel (PTX)-resistant cell
lines (SKpac) were produced from the parent cell line
(SKOV3) by continuous exposure of a stepwise, escalat-
ing concentration of PTX from an IC50 of 10% to 1000%
over a period of 12 months. Seven different sublines
(SKpac-8, -10, -11, -12, -13, -16, and −17) were gener-
ated. SKpac cells were 365.5-fold more resistant to PTX
(IC50 = 10.21 μM, 7.59 μM, 6.77 μM, 6.57 μM, 8.69 μM,
8.38 μM, and 5.32 μM, respectively) than that of the
SKOV3 cell line (IC50 = 22 nM). All cell lines were
maintained in 5A medium (Gibco/Invitrogen, Carlsbad,
CA, USA) with 10% fetal bovine serum (FBS) (Invi-
trogen), 100 U/mL penicillin, and 50 μg/mL strepto-
mycin in a humidified atmosphere containing 5% CO2 at
37°C. The primary tumor cells were obtained at the time
of surgery from patients who had undergone oophorec-
tomy for ovarian serous carcinoma. Tumors were mech-
anically dissected into single-cell suspensions and
incubated at 37°C for 1 hour in Ca2+/Mg2+-free PBS
containing 50 U/ml collagenase A (Roche, Pleasanton,
CA, USA). The enzymatic reaction was blocked by
adding RPMI medium (Gibco/Invitrogen) containing
10% FBS. Cells were reacted with BerEP4-coated mag-
netic Dynal beads (Invitrogen) for 30 min to select epi-
thelial cells and then cultured with RPMI medium
containing 10% FBS, 1% penicillin-streptomycin, and 10
μg/ml of endothelial cell growth factor (Invitrogen).Thirty-four ovarian carcinomas were obtained at the
time of surgery from patients who had undergone oo-
phorectomies for ovarian epithelial tumors at the CHA
Bundang Medical Center. The samples were immediately
frozen in liquid nitrogen and stored at −80°C. Tumor
cells comprised nearly 80% of frozen section tissue.
Clinical and pathological data were retrieved from
clinical databases including the original pathology
reports with histological grade and tumor stage. A histo-
pathological examination of these samples was per-
formed in the Department of Pathology according to the
criteria of the International Federation of Gynecology
and Obstetrics grading system and the World Health
Organization classification. The patient’s samples were
devided into two groups according to the responsiveness
to the first-line chemotherapy. Based on the NCCN
guidelines, intrinsically chemoresistant tumors were de-
fined as those with persistent or recurrent disease within
6 months after the initiation of first-line taxol-platinum-
based combination chemotherapy. Chemosensitive tu-
mors were classified as those with a complete response
to chemotherapy and a platinum-free interval of >6
months. This study was approved by the Ethical Com-
mittee of the CHA Bundang Medical Center, and in-
formed consent was obtained from each patient prior to
surgery. The clinicopathological data are summarized in
Table 1.
ALDEFLUOR assay and fluorescence-activated cell sorting
(FACS)
The ovarian cancer cell line (SKOV3), chemoresistant
sublines (SKpac-12, 16, and 17), and primary ovarian
tumor cell suspensions were counted and ALDH en-
zymatic activity was detected using the ALDEFLUOR
assay kit (StemCell Technologies Vancouver, BC,
Canada) as described by the manufacturer. Half of the
cell/substrate mixture in each sample was treated with
50 mM diethylaminobenzaldehyde (DEAB), and the
cells were incubated for 40 minutes. Gating was
established using propidium iodide (PI) exclusion for
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used to define negative gates. FACS was performed
with 1 × 106 cells using the BD FACS Aria III (Becton
Dickinson, Franklin Lakes, NJ, USA) under low pressure
in the absence of UV light. FACS data were analyzed
using BD FACS Diva software V6.1.3.
RT-PCR analysis of stem cell marker genes
Semiquantitative RT-PCR was performed to assess the
amount of stemness-related gene mRNA in ALDH1(+)
cells compared with that in ALDH1(−) cells. Total RNA
was extracted from ALDH1(+) or ALDH1(−) cells ac-
quired by FACs sorting using Trizol reagent (Invitrogen).
RNA (1 μg) was reverse-transcribed in a total volume of
20 μl using the SuperScript First-strand Synthesis system
(Invitrogen). The primers for these genes are listed in
Table 2. The PCR products were loaded on a 2% agarose
gel, the ethidium bromide stained gel image was digita-
lized using the Molecular Imager Gel Doc™ XR System
(Bio-Rad, Hercules, CA, USA), and calculated by densi-
tometry. GAPDH was used as the reference gene to
normalize mRNA amounts between samples. Results are
presented as relative mRNA expression of each gene to
that of GAPDH mRNA.
Spheroid formation assay
The FACS-sorted ALDH1 (+) or ALDH1(−) cells were
plated in wells of an ultra-low attachment surface 6-well
culture plate (Corning, Acton, MA, USA) at a density of
3,000 cells/ml in serum-free DMEM/F12 medium
(Invitrogen) supplemented with 20 ng/ml epidermal
growth factor (Invitrogen), 10 ng/ml basic fibroblastTable 2 Primer sequence of stemness-related genes
Gene Primer sequence
Notch3 F: 5′- TCT TGC TGC TGG TCA TTC TC-3′
R: 5′-TGC CTC ATC CTC TTC AGT TG-3′
Oct4 F: 5′-GGA AAG GCT TCC CCC TCA GGG AAA GG-3′
R: 5′-AAG AAC ATG TGT AAG CTG CGG CCC-3′
NAC1 F: 5′-CCA GAC ACT GCA GAT GGA GA-3′
R: 5′-AAG CTG AGG ATC TGC TGG AA-3′
c-Kit F: 5′-GGC ATC ACG GTG ACT TCA AT-3′
R: 5′-GGT TTG GGG AAT GCT TCA TA-3′
BMI1 F: 5′-TTA CCT GGA GAC CAG CAA GT-3′
R: 5′-CAT TAG AGC CAT TGG CAG CA′3′
Nanog F: 5′-AGA AGG CCT CAG CAC CTA C-3′
R: 5′-GGC CTG ATT GTT CCA GGA TT-3′
Sox-2 F: 5′-GCG CGG GCG TGA ACC AG-3′
R: 5′-CGG CGC CGG GGA GAT ACA-3′
GAPDH F: 5′-ACC ACA GTC CAT GCC ATC AC-3′
R: 5′-TCC ACC ACC CTG TTG CTG TA-3′growth factor (Sigma-Aldrich, St Louis, MO, USA), 0.4%
bovine serum albumin (Sigma-Aldrich), and 5 μg/mL in-
sulin (Sigma-Aldrich). Spheroid formation (each with
50–100 cells/sphere) was assessed 12 days after seeding.
miRNA microarray
miRNA expression profiles of the FACS-isolated ALDH1(+)
or ALDH1(−) cells from four PTX-resistant SKpac cell
lines (SKpac-16-#1,-16 #2, -17#1, and −17#2) were
determined with an Affymetrix GeneChipW miRNA
array to select candidate miRNAs associated with
ALDH1. The samples were prepared according to the
manufacturer’s instructions. Total miRNA was isolated
using TriZol reagent (Invitrogen), and RNA quality
was assessed with an Agilent 2100 Bioanalyzer using
the RNA 6000 Nano Chip (Agilent Technologies,
Amstelveen, The Netherlands). One μg of total RNA
was used as input for the labeling reaction, and labeled
miRNA was hybridized to the array for 16 hours at
48°C and 60 rpm as described in the protocol. After
hybridization, the chips were stained and washed in a
Genechip Fluidics Station 450 (Affymetrix) and scanned
with a Genechip Array scanner 3000 7G (Affymetrix).
Validation of ALDH1 and selected miRNA expression
levels by qRT-PCR
We performed real-time qRT-PCR for ALDH1 and six
selected miRNAs that showed significantly altered ex-
pression in ALDH1(+) cells compared with ALDH1(−)
cells to validate the ALDEFLUOR assay and the micro-
array data. The qRT-PCR for ALDH 1 was conducted
with ALDH1(+) or ALDH1(−) cells from SKpac-12, 16,
and 17 cells. One μg of total RNA was converted to
cDNA with the SuperscriptIII First-strand Synthesis
System (Invitrogen) and qRT-PCR was conducted with
specific primers and a probe for ALDH1. For miRNAs,
one μg of total RNA was reverse transcribed to cDNA
using stem-loop specific RT-primers of mature miRNAs
and a TaqMan MicroRNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA, USA). The qRT-
PCR was performed with a Taqman Universal Master
Mix (Applied Biosystems) using the Bio-Rad CFX96
Real-Time PCR Detection System (Bio-Rad). All PCR re-
actions were run in triplicate, and gene expression rela-
tive to GAPDH (for ALDH1) or RNU48 (for miRNAs)
was calculated using the comparative threshold method
(2-ΔΔCt). Results for the ALDH1 (+) cells are expressed
as fold-change relative to ALDH1 (−) cells.
We also conducted the qRT-PCR in various ovarian
cancer cell lines (SKOV3, SKpac-8, 10, 11, 12, 13, 16,
and 17) and 34 ovarian serous carcinoma samples in-
cluding 15 chemoresistant and 19 chemosensitive car-
cinomas to assess the association ALDH1 and ALDH1
(+)-related miRNA expression with chemoresistance.
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changes of chemoresistant SKpac cells relative to the level
of parent SKOV3 cells. The results for carcinoma samples
are expressed as fold-change relative to the mean level of
three normal ovarian surface epithelial cells.
Results
Subpopulations of ALDH1 (+) cells in the ovarian cancer
cell lines
We examined the population of ALDH1(+) cells, a
potential cancer stem cell marker, in various ovarian
cancer cell lines (SKOV3, A2780, and OVCAR 3),
chemoresistant sublines (SKpac-12,-16,-17, A2780pac,
and A2780cis), and primary tumor cells (SCN-1–7). The
ALDH1(+) cells varied considerably among ovarian can-
cer cell lines with a range of 0.9–17.2% and with a range
of 0.4–4.0% among the primary cancer cells (Table 3).
The ALDH 1(+) population percentage by FACS ana-
lysis in chemoresistant SKpac cells (4.46 ± 0.71%) in-
creased significantly (Figure 1A,B) compared with that
in parental SKOV3 cells (0.9 ± 0.2%), suggesting an asso-
ciation between ALDH 1(+) cells and chemoresistance.
We performed qRT-PCR for ALDH1 mRNA to con-
firm whether FACS-sorted ALDH1 (+) cells showed in-
creased ALDH1 expression. The FACS-sorted ALDH1
(+) population showed 2–5 fold higher expression of
ALDH1 mRNA compared with that in the ALDH1(−)
population (Figure 1C).
RT- PCR analysis of stemness markers in ALDH1(+) and
ALDH1 (−) cells
The stem cell phenotype of the ALDH1(+) cells was
confirmed by expression of several stemness-associatedTable 3 Population of ALDH1 (+) cells as determined by
the ALDEFLUOR assay in various human ovarian cancer
cell lines and primary cells
Cells % ALDH1 (+) cell
SKOV3 0.9 ± 0.2
Skpac 4.46 ± 0.71











SCN, primary ovarian cancer cells.markers for Notch3, Oct-4, NAC1, c-Kit, BMI-1, Nanog,
and SOX2 using semiquantitative RT-PCR. The mRNA
expression of Notch3 (1.73-fold) was significantly higher
(t-test, p = 0.04) in ALDH1(+) cells than that in ALDH1
(−) cells (Figure 2A). Oct-4 (1.19-fold), NAC1 (1.39 -fold),
and Sox2 (1.26-fold) mRNA levels tended to be elevated
in ALDH1(+) cells compared with those in ALDH1(−)
cells, but the difference was not significant. BMI-1 (1.02-
fold), c-Kit (1.16-fold), and Nanog (1.05-fold) mRNAs
were not differentially expressed.
Spheroid formation assay of ALDH1 (+) and ALDH1 (−)
cells
We compared the spheroid formation capability between
ALDH1 (+) and ALDH 1(−) cells to test the stem cell-
like property. ALDH1(+) cells showed increased size and
number (106 ± 37) of spheroids compared with ALDH1
(−) cells (63 ±15) (Figure 2B) (t-test, p = 0.05).
Implication of ALDH1-positivity for chemoresistance and
clinicopathological parameters
We examined ALDH1 mRNA expression in ovarian can-
cer cells and 34 cases of ovarian cancer tissue sam-
ples using qRT-PCR. The expression levels of various
chemoresistant SKpac cells were compared with those of
the chemosensitive SKOV3 parent cell line. ALDH1
mRNA expression in chemoresistant SKpac cells was
markedly elevated (17 ~ 124-fold) compared with that in
SKOV3 (Figure 3A). The ALDH1 mRNA expression
level relative to that of normal epithelial cells was calcu-
lated and compared between chemosensitive and
chemoresistant groups in the human cancer tissue sam-
ples. The relative expression level of ALDH1 mRNA
(Figure 3B) in the chemoresistant group of human can-
cers (11-fold) was significantly higher (t-test, p = 0.024)
than that of the chemosensitive group (4.29-fold).
To assess the role of ALDH1 in ovarian cancer, we an-
alyzed the relationship of ALDH1 mRNA expression
with clinicopathological parameters, including clinical
stages, lymph node metastasis and distant metasta-
sis. For comparison, patients were classified into high
(≥2-fold) and low (<2-fold) ALDH1 expression groups.
The high expression of ALDH1 mRNA was significantly
(p = 0.019) associated with advanced clinical stage
(Figure 3C). The ALDH 1 expression was not correlated
with lymph node or distant metastases.
microRNA expression patterns in ALDH1(+) cells assessed
by microarray
We performed the Affymetrix GeneChip microarray
analysis containing 4,560 human precursor and mature
miRNA oligonucleotide probes to characterize the
miRNA expression profile of ALDH1 (+) cells. As a re-
sult, six miRNAs were differentially overexpressed more
Figure 1 Population of ALDH1(+) cells in ovarian cancer cells. A. ALDH1 enzymatic activity in chemosensitive SKOV3 and chemoresistant
SKpac16 cells as determined by the Aldefluor assay. DEAB is a specific inhibitor of ALDH1 and was used to confirm gating areas. B. A comparison
of the percentage of ALDH1(+) in SKOV3 cells and chemoresistant SKpac-12, -16, and −17 cells. C. ALDH1 mRNA expression in FACS-sorted
ALDH1 (+) and (−) cells. All data are representative of at least two independent experiments. (*p < 0.05).
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ALDH1 (−) cells (Table 4, Figure 4A) (miR-424 [1.98-fold],
miR-346 [1.95-fold], miR-503 [1.86-fold], miR-27a [1.66-
fold], miR-23b [1.53-fold], and miR-27b [1.50-fold]). No
miRNAs were downregulated in ALDH1 (+) cells.
We compared expression of six differentially expressed
miRNAs between ALDH1(+) and ALDH1(−) cells using
real-time RT-PCR to validate the microarray results. As
a result, miR-424 (1.62-fold), miR-346 (3.25-fold), miR-
503 (1.66-fold), miR-27a (2.08-fold), miR-23b (1.98-fold),
and miR-27b (3.09-fold) were upregulated in ALDH1 (+)
cells relative to ALDH1 (−) cells (Figure 4B).
Implication of ALDH1(+)-associated miRNAs in
chemoresistance and clinicopathological parameters of
ovarian cancer
We examined the expression of these miRNAs in ovar-
ian cancer cells and 34 cases of ovarian cancer tissue
samples using qRT-PCR to assess the impact of six
ALDH1(+)-related miRNAs on chemoresistance in ovar-
ian cancers. The expression levels of various che-
moresistant SKpac cells were compared with those of
the chemosensitive SKOV3 parent cell line. Among themiRNAs examined, the expression levels of miR-23b
(2.8-fold, p = 0.039), miR-27b (3.5-fold, p = 0.007),
miR-346 (2.7-fold, p = 0.02), and miR-503 (2.2-fold,
p = 0.049) were significantly higher than those in
SKOV3 cells (Figure 5A).
The expression levels of miRNAs in the human cancer
tissue samples relative to those of normal epithelial cells
were calculated and compared between the chemosensitive
and chemoresistant groups. The expression levels of miR-
23b (3.5-fold vs. 0.6-fold p = 0.037), miR-27b (5.5-fold vs.
1.6-fold, p = 0.040) and miR-424 (2.0-fold vs. 0.7-fold,
p = 0.047) were significantly higher in the chemoresistant
group than those in the chemosensitive group (Figure 5B).
We analyzed the correlation between the expression of
these miRNAs and clinicopathological parameters, in-
cluding clinical stage, lymph node metastasis, and
distant metastasis to verify the role of ALDH1(+)-associ-
ated miRNAs in ovarian cancer. Patients were classified
into high (≥1.5-fold) and low (<1.5-fold) expression
groups. High expression of miR-503 (Figure 5C) was sig-
nificantly associated (p = 0.033) with advanced clinical
stage (stage III and IV), and upregulation of miR-27a
(Figure 5D) was related to distant metastasis (p = 0.046).
Figure 2 ALDH1(+) cells show stem cell properties. A. mRNA expression of stemness-associated genes, particularly Notch 3, increased in
ALDH1(+) cells compared with that in ALDH1(−) cells. The graph represents the relative fold expression of band density normalized to that of
GAPDH (*p < 0.05). B. The spheroid formation assay revealed an increased number of spheroids in ALDH1(+) cells. The graph presents the
average spheroid formation in ALDH1(+) and ALDH1(−) cells (*p < 0.05). All data are representative of at least two independent experiments.
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ological parameters.
Discussion
CSCs comprise a very small proportion (0.01–1.0%) of
malignant tumors but are believed to be the source of
recurrent tumors and of resistance to chemotherapy and
radiotherapy due to their ability to survive conventional
treatments, which usually target rapidly dividing cells
[7,13]. Therefore, identifying CSCs and their molecular
phenotype might serve to develop a new therapeutic
strategy for lethal human cancers including ovarian car-
cinoma. Indeed, several studies focusing on identifying
and characterizing ovarian CSCs have been reported re-
cently [14-16]. These studies suggested several markers
including CD44, CD117, CD133, and ALDH1 as pos-
sible ovarian CSC markers. Among them, ALDH1 is
considered to be a consistent ovarian CSC marker iden-
tified in all ovarian cancer cell lines and primary humancancer samples [15]. Therefore, we used ALDH1 as a
putative ovarian CSC marker in the present study and
confirmed that ALDH1(+) cells were enriched with ovar-
ian CSCs by demonstrating an increased expression of
stem cell markers and increased spheroid formation abil-
ity compared with those in ALDH1(−) cells.
A growing body of evidence indicates that miRNAs
regulate most human genes in crucial biological pro-
cesses including tumorigenesis, progression, and therapy
resistance. MiRNAs also seem to be involved in control-
ling CSC self-renewal and differentiation, according to
more recent studies reporting differentially expressed
miRNAs in CSCs of various human cancers [17-19]. Re-
cently, deregulation of some miRNAs, such as miR-200a,
miR-199a, and miR-214, were reported in CD133(+) or
CD44(+) ovarian CSCs [20]. However, only limited data
are available regarding microRNA expression profiles in
ovarian CSCs. Therefore, we identified ovarian CSC-
specific miRNAs using high-throughput microRNA
Figure 3 ALDH1-positivity was associated with chemoresistance in ovarian cancer cells and tumor tissues. A. ALDH1 mRNA expression
by qRT-PCR in various chemoresistant SKpac sublines. Relative expression levels are normalized to parent SKOV3 cells. B. ALDH1 mRNA expression
by qRT-PCR in chemoresistant ovarian cancer tissues was significantly higher than that in the chemosensitive group. C. To verify the role of
ALDH1 in ovarian cancer, we analyzed the correlation between ALDH1 mRNA expression and clinicopathological parameters, including clinical
stage, lymph node metastasis, and distant metastasis. Patients were classified into high (≥2-fold) and low (<2-fold) expression groups for
comparison. High ALDH1 mRNA expression was significantly (p = 0.019) correlated with advanced clinical stage.
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differentially expressed miRNAs with chemoresistance in
ovarian cancer.
We found that six miRNAs, including miR-23b, miR-
27a, miR-27b, miR-346, miR-424, and miR-503, were sig-
nificantly overexpressed in CSC-enriched ALDH1(+)
cells using miRNA microarray and qRT-PCR. We dem-
onstrated that these miRNAs and ALDH1 increased sig-
nificantly in chemoresistant SKpac sublines compared
with those in the chemosensitive SKOV3 cell line,
suggesting that these miRNAs and ALDH1 are associ-
ated with ovarian cancer chemoresistance. To validate
the relationship of ALDH1 and ALDH1-related miRNAs
with chemoresistance, we further studied the expression
of ALDH1 and these miRNAs in human ovarian cancer
samples. Consistent with the results of the ovarian cellTable 4 MicroRNAs significantly altered (>1.5 fold) in ALDH1(
Name Absolute fold change P-value Chromosom
hsa-miR-424 1.98 0.02 Xq26.3
hsa-miR-346 1.95 0.01 10q23.2
hsa-miR-503 1.86 0.05 Xq26.3
hsa-miR-27a 1.66 0.03 19p13.13
hsa-miR-23b 1.53 0.02 9q22.32
hsa-miR-27b 1.50 0.03 9q22.32
The target genes presented are predicted using the TargetScan (http://www.targetslines, ALDH1 mRNA expression in the chemoresistant
group was significantly higher (2.5-fold) than that in the
chemosensitive group, and the expression of miR-23b,
miR-27b, and miR-424 was significantly upregulated in
the chemoresistant group. Upregulation of ALDH1 and
miR-503 correlated with high clinical stage, and
upregulation of miR-27a was correlated with distant
metastasis.
Our result showing the correlation between high
ALDH1 expression and chemoresistance agrees with
some other recent breast and ovarian cancer studies
[21-23]. The present study also demonstrated that PTX-
resistant subclones (SKpac cells) were more enriched in
ALDH1(+) cells compared with their parental SKOV3
cells. We also found higher ALDH1 expression in
chemoresistant ovarian cancer tissues compared with+) cells compared with ALDH1 (−) cells in ovarian cancer
e Putative target genes
WEE1, CDCA4, USP15, LATS2, HIPK2
PTPN18, LIF
CDCA4
GSPT1, CDS1, TAB3, SFRP1, MDM4, PRKCB, SESN2, FOSB, SMAD2
APAF1, PPP2R5E, PPP1CB, PPIF, REPS2, CHUK
GSPT1, CDS1, TAB3, PRKCB
can.org) and PicTarVert (http://pictar.mdc-berlin.de) softwares.
Figure 4 MicroRNAs differentially overexpressed in ALDH1 (+) cells compared with ALDH1 (−) cells. A. Hierarchical clustering of miRNA
expression profiles by miRNA microarray. Unsupervised hierarchical clustering analysis of miRNAs that exhibited a statistically significant (p < 0.05)
increase or decrease in ALDH1 (+) cells compared to ALDH1 (−) cells. The miRNA expression level is color-coded. B. Validation of candidate
miRNAs expression by qRT-PCR. The bar graph shows the expression of each microRNA in flow cytometry-sorted ALDH1 (+) cells relative to the
average expression level in ALDH1 (−) cells. Representative experiments repeated three times (*p < 0.05).
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clonal selection of intrinsic ALDH1(+) cells by chemo-
therapy may increase ALDH1 expression in chemo-
resistant cancer cells and may allow the acquisition of
chemoresistance in residual cancers. Chang et al. [24]
reported a correlation between low ALDH1 expression
and advanced cancer stage and response to cisplatin
treatment. However, Chang et al. included hetero-
geneous subtypes of ovarian cancer, including the
endometrioid and mucinous types, and used immuno-
histochemical staining with a tissue microarray, which
may not represent the characteristics of the whole
tumor. More recent studies [15,23] have suggested an
association between high ALDH1 expression and ad-
vanced cancer stage and poor response to chemotherapy,
consistent with our results. Taken together, targeting
ALDH1 in ovarian cancer may be a new strategy to treat
chemoresistant and advanced ovarian carcinoma.
In the present study, miR-23b, miR-27b, and miR-424
were significantly upregulated in the chemoresistanthuman cancer group among six miRNAs differentially
overexpressed in ALDH1(+) cells. MiR-23b has been
reported to function as a renal cancer oncogene [25],
similar to ovarian cancer seen in the present study,
whereas it functions as a tumor suppressor in hepatocel-
lular carcinoma [26]. The introduction of pre-miR-27b
stimulates invasion in breast cancer cells by targeting
the ST14 tumor suppressor [27], and is upregulated in
glioma cells and tumor tissues [28]. However, it is
downregulated in lung cancer tissue [29]. A recent study
for miRNAs expression signatures in tumorigenesis [30]
indicated that miR-424 was associated with angiogenesis,
and that miR-23b and miR-27b were upregulated in
metastatic stage. They also demonstrated that miR-424
were up-regulated in metastases compared with pri-
mary tumors in both mice and human pancreatic neuro-
endocrine tumors. Another study for non-small cell lung
cancers demonstrated that up-regulation of miR-424 was
related with poor prognosis [31]. On the other hand, it
was reported that low expression of miR-424 was
Figure 5 ALDH1 (+)- related miRNAs are associated with chemoresistance in ovarian cancer cells and tumor tissues. A. A comparison of
miRNA expression in SKOV3 and chemoresistant SKpac cells. miRNAs-23b, -27b, -346, and −503 were significantly upregulated in SKpac cells
compared with SKOV3 parent cells. B. Expression of ALDH1 (+)-related miRNAs by qRT-PCR in chemosensitive and chemoresistant ovarian cancer
tissues. Relative expression levels were normalized to those of normal epithelial cells. Expression levels of miRNAs-23b, -27b, and −424 were
significantly upregulated in the chemoresistant group compared with those in the chemosensitive group. Representative experiments repeated
three times (*p < 0.05). C. High expression of miR-503 significantly correlated (p = 0.033) with advanced clinical stage (stage III and IV).
D. Upregulation of miR-27a was associated with distant metastasis (p = 0.046).
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node metastasis and other poor prognostic parameters
in cervical cancers [32]. Taken together, the oncogenic
function of miR-23b, miR-27b, and miR-424 seems to be
cell type- and context-specific.
The upregulation of miR-27a didnot show a statistically
significant correlation with chemoresistance in the valid-
ation with paclitaxel-resistant SKpac sublines and patient’s
samples in this study. However, a previous study reported
that miR-27a was upregulated in paclitaxel-resistant ovar-
ian cancer cell line A2780/Taxol as compared with its
parental line A2780 [33]. In the present study, high ex-
pression of miR-27a was related with distant metastasis
suggesting its role on the progression of ovarian cancer.
The function of miR-503 in tumor development and
progression remains unresolved except for a report dem-
onstrating its regulation of metastatic function in hepa-
tocellular cancer cells [34]. Therefore, we searchedpredicted target genes associated with apoptosis and
tumor suppression via web-based computational pro-
grams such as Target Scan (http://www.targetscan.org)
and PicTar-Vert (http://pictar.mdc-berlin.de) to predict
the role of miR-503 implicated in chemoresistance and
tumor progression. CDCA4, a putative miR-503 target
gene with a high target score, participates in the regula-
tion of cell proliferation mainly through the E2F/pRB
pathway [35]. Further studies are necessary to determine
whether miR-503 induces cancer cell growth or migra-
tion/invasion, and whether CDCA4 is a direct target
gene of miR-503, as well as to define the oncogenic
function of miR-503 in this subset of ovarian cancers.
Conclusions
We demonstrated in this study that ALDH1 is a marker
for enriching ovarian CSCs, and that high ALDH1 expres-
sion is associated with chemoresistance and high clinical
Park et al. Journal of Ovarian Research 2013, 6:18 Page 10 of 11
http://www.ovarianresearch.com/content/6/1/18stage. Six miRNAs, including miR-23b, miR-27a, miR-27b,
miR-346, miR-424, and miR-503 were overexpressed in
ALDH1(+) cells, and significantly implicated in chemo-
resistance in ovarian cancers. Upregulation of miR-503
correlated with high clinical stage, and upregulation of
miR-27a was related with distant metastasis in patients
with ovarian cancer.
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